Loading…
← CockpitCompetitor Analysis › 4985.T Earth CorporationOpen in the cockpit ↗

Earth Corporation4985.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major
Momentum strong 67
Mkt cap
$687M
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$1.83M
20-day average traded
Fwd P/E
18.0×
forward earnings
ROIC−WACC
+1.2 pp
WACC 5.0%
Hurdle
+0 pp
Req g minus delivered
Next earnings
89 days
15 Feb 2027
Close · JPY¥4,930
1D-1.0%
1W+1.6%
1M+0.1%
3M+1.9%
6M+6.9%
YTD-0.7%
1Y-2.2%
ATR %1.7%
52w lowhigh6.1% off high

What Earth does

Employees: 4,963

Earth at a glance

Size Earth (4985.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $687M, the 921st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,930 on 18 Nov 2026.

Performance Over six months the shares gained 6.9%, against -10.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 4.4% over the last twelve months (peer median +4.3%); the operating margin is 3.6% (peer median 12.4%).

Valuation It trades at 18.0× forward earnings against a peer median of 14.9× (5th most expensive of 11).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 20264985.T 106Peer median 92
Six months, rebased to 100: Earth against the median of its 20 peers (local-currency closes).

Earth financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥185B¥179B¥169B¥158B¥152B
Revenue growth—+6%+7%+4%—
Gross profit¥73.5B¥72.6B¥66.8B¥61.8B¥60.6B
EBITDA¥11.7B¥12.8B¥11.0B¥10.6B¥11.7B
Net income¥3.78B¥5.24B¥3.48B¥4.10B¥5.30B
Free cash flown/a¥7.85B¥10.1B¥3.08B-¥992M
Capital expendituren/a¥4.17B¥4.77B¥6.04B¥5.89B
Total debt¥1.61B¥7.92B¥5.24B¥10.2B¥2.40B

Quarterly statements and history in the cockpit →

Earth competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%+10%000915600351NVCT688658600829PHIL688488ANNX4534SPARC0570SGMTFDC600530688566INNOVACAP00056621864985.T6-month return →1-month return →
Up and to the right = strong over both horizons. Earth is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×50×100×000915688658PHIL6884884534603998688799688566INNOVACAP21864985.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Earth is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600351600829688488603998FDC600530688566INNOVACAP21864985.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Earth is the large dot.

Earth competitors and peer comparison

How Earth compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Earth against its 20 peers (data as of 18 Nov 2026)
Measure4985.TPeer medianRank in peer set
1-month return+0.1%-4.3%7th highest of 21
6-month return+6.9%-10.1%4th highest of 21
Distance from 52-week high-6.1%-32.9%highest of 21
Revenue growth (TTM)+4.4%+4.3%9th highest of 18
Operating margin3.6%12.4%6th lowest of 18
Forward P/E18.0×14.9×5th most expensive of 11
Growth the price implies (Req g, 7 yrs)-1.6%5.9%4th least demanding of 10
Growth delivered (Del g)-1.8%+6.4%2nd lowest of 10
Hurdle (Req g minus delivered)+0.2 pp-4.3 pp4th most demanding of 10
ROIC minus cost of capital+1.2 pp+0.0 pp6th highest of 16
EV / EBITDA8.4×3.8×3rd most expensive of 8
Net debt / EBITDA-1.5×-1.2×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Youcare Pharmaceutical 688658.SSChina$674M-49%-7%-13%24.9×n/an/a
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
Philogen PHIL.MIItaly$672M-11%+295%79%10.1×n/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%112.1×31.9%+19.8%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%n/an/an/a
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
FDC FDC.NSIndia$653M+3%+10%14%n/a25.2%+10.3%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%32.2×27.1%+31.4%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%n/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%

Questions

Which companies are Earth's closest peers?
The cockpit's peer set: Shandong Wit Dyne Health (000915.SZ), Yabao Pharmaceutical (600351.SS), Nuvectis Pharma (NVCT), Youcare Pharmaceutical (688658.SS), HPGC Renmintongtai Pharmaceutical (600829.SS), Philogen (PHIL.MI), Jiangsu Aidea Pharmaceutical (688488.SS), Annexon (ANNX).
Is Earth expensive compared with its peers?
On forward p/e it trades at 18.0× against a peer median of 14.9×, 5th most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Earth stock performed?
Over six months to 18 Nov 2026 the shares returned +6.9% against -10.1% for the median peer; over one year -2.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.